<DOC>
	<DOCNO>NCT00278252</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , etoposide , work different way stop growth tumor cell , either kill cell stop dividing . PURPOSE : This phase II trial study well etoposide work treat young patient ependymoma .</brief_summary>
	<brief_title>Etoposide Treating Young Patients With Relapsed Ependymoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine response rate young patient relapse and/or refractory ependymoma treat rapid schedule intravenous etoposide . Secondary - Determine possibility second surgery additional radiotherapy patient . OUTLINE : This multicenter study . Patients receive etoposide IV 1 hour day 1-3 , 8-10 , 15-17 . Treatment repeat every 28 day 6 course absence disease progression unacceptable toxicity . Patients whose tumor become resectable course 3 6 undergo surgical resection . After completion study treatment , patient follow periodically approximately 5 year . PROJECTED ACCRUAL : At least 14 patient accrue study .</detailed_description>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Ependymoma</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm intracranial ependymoma first , second , third relapse Anaplastic ( malignant ) lowgrade ependymoma ( cellular , papillary , clear cell , mixed variant ) Unequivocal evidence tumor recurrence progression MRI scan fail conventional treatment ( e.g. , primary surgery adjuvant radiotherapy ) initial recurrent disease Unresectable disease OR amenable complete surgical resection Measurable enhance nonenhancing disease baseline scan perform within past 2 week Patients undergone prior surgery must residual measurable disease PATIENT CHARACTERISTICS : Lansky performance status 30100 % Life expectancy â‰¥ 8 week Absolute neutrophil count &gt; 1,000/mm^3 Platelet count &gt; 100,000/mm^3 Serum total bilirubin normal AST &lt; 2 time upper limit normal No unrelated medical condition ( e.g. , renal liver impairment ) would preclude chemotherapy treatment No active infection No known HIV positivity PRIOR CONCURRENT THERAPY : See Disease Characteristics No radiotherapy within past 6 week No chemotherapy within past 4 week Prior IV etoposide allow</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>recurrent childhood ependymoma</keyword>
	<keyword>childhood infratentorial ependymoma</keyword>
	<keyword>childhood supratentorial ependymoma</keyword>
</DOC>